When physicians on GLP-1s for weight loss disclosed that fact, patients on the drugs said they feel understood, less judged, and not shamed. They may also be more likely to follow the care plan.
"My weight has always been kind of an issue," said Gerald Fernandez, a 33-year-old mortgage broker in Naples, Florida . Over the years, he has sought advice from his physicians but felt unsatisfied with the guidance he has received:"They never gave me a solution, besides 'Work out more, eat less.'"Earlier this year, Fernandez found a new clinician who suggested he take a glucagon-like peptide 1 receptor agonist for weight loss .
"I do videos, I talk about it a lot," she said. Toomer said she has lost more than 100 lb — 60 of that before going on the medications, then another 45+ after she started taking a GLP-1. With her patients, she focuses on managing expectations, such as fast weight loss, driven by what people may see on social media.
A common response from his patients to his story:"No one has ever explained this to me so well." They appreciate the real-life application he provides for their own treatment plan, he said. "It's never a good idea to access these medications without evaluation by a healthcare professional for obesity complications and related diseases, and with ongoing follow-up," agreedSelf-prescribing"is always a bad idea," said Arthur Caplan, PhD, head of medical ethics at NYU Grossman School of Medicine, in New York City, and a frequent contributor to.
Obese Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Weight Management Weight Loss Florida Medical Life Physician Lifestyle Medical Lifestyle Resident Lifestyle Medical Student Lifestyle Nurse Lifestyle Hospitalists Residency Residents South Carolina Ethics
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
JPMorgan says there's a new GLP-1 drug player and its shares can rally 80%Structure Therapeutics could one day boast a competitive obesity product an go up against Eli Lilly and the like, according to JPMorgan.
Read more »
Eli Lilly's big GLP-1 investment — plus, what we want from 4 portfolio stock earningsThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »
Use of GLP-1 Meds Have Risen 7-Fold Among Young AmericansThe number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report finds.
Read more »
GI Complications With GLP-1s for Weight Loss: Reexamining the RisksAfter a 2023 study linked GLP-1s to an increased risk for pancreatitis, gastroparesis, and bowel obstruction, other researchers did a retrospective study to reexamine the association.
Read more »
How digital health companies are capitalizing on the GLP-1 boomJoining the market for GLP-1s is a massive opportunity, and digital health companies from Ro to WeightWatchers are battling for market share.
Read more »
Forget Ozempic and Wegovy — Utahns embracing natural solution to boost GLP-1Given the potential side effects of GLP-1 prescription drugs, many Utahns are seeking alternative methods to naturally boost GLP-1 levels in the body.
Read more »